A prospective study comparing the efficacy of Budesonide nasal douching vs. Fluticasone nasal spray in Post FESS patients.
The study assessed and compared the efficacy of Budesonide steroid nasal douching versus Fluticasone nasal spray in preventing recurrence of symptoms and nasal polyps post-FESS.
A prospective cohort study conducted in the Department of ENT, Saveetha Medical College and Hospital, Thandalam from June 2022 to June 2023 involving 60 patients diagnosed as Chronic sinusitis with polyposis were scheduled for FESS. Inclusion criteria included adults aged 18 and above with a confirmed diagnosis based on clinical symptoms, endoscopic findings, and radiological imaging. The severity of CRS was evaluated with SNOT22 score and Lund-Kennedy Endoscopic grading system. Patients were randomly assigned to two groups: Group A which was started on Budesonide nasal irrigation twice a day, and Group B, which received Fluticasone nasal spray.
The average age of participants were 33.23 years, with an even distribution between females and males. Preoperative SNOT-22 and Lund-Kennedy scores were similar between both groups. One month postoperatively, both the groups had similar SNOT22 scores, but the Budesonide group had significantly lower Lund-Kennedy scores. At three months, no significant differences were observed. However, at six months, the Budesonide group had significantly lower SNOT22 and Lund-Kennedy scores when compared to the patients receiving Fluticasone.
While Budesonide and Fluticasone are both effective post-FESS treatments, Budesonide nasal irrigation may offer better long-term symptom control and endoscopic outcomes. The broader nasal coverage achieved through nasal douching could contribute to its enhanced therapeutic effect.
A prospective cohort study conducted in the Department of ENT, Saveetha Medical College and Hospital, Thandalam from June 2022 to June 2023 involving 60 patients diagnosed as Chronic sinusitis with polyposis were scheduled for FESS. Inclusion criteria included adults aged 18 and above with a confirmed diagnosis based on clinical symptoms, endoscopic findings, and radiological imaging. The severity of CRS was evaluated with SNOT22 score and Lund-Kennedy Endoscopic grading system. Patients were randomly assigned to two groups: Group A which was started on Budesonide nasal irrigation twice a day, and Group B, which received Fluticasone nasal spray.
The average age of participants were 33.23 years, with an even distribution between females and males. Preoperative SNOT-22 and Lund-Kennedy scores were similar between both groups. One month postoperatively, both the groups had similar SNOT22 scores, but the Budesonide group had significantly lower Lund-Kennedy scores. At three months, no significant differences were observed. However, at six months, the Budesonide group had significantly lower SNOT22 and Lund-Kennedy scores when compared to the patients receiving Fluticasone.
While Budesonide and Fluticasone are both effective post-FESS treatments, Budesonide nasal irrigation may offer better long-term symptom control and endoscopic outcomes. The broader nasal coverage achieved through nasal douching could contribute to its enhanced therapeutic effect.